Researchers at Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. (dba Bridgebio Oncology Therapeutics) have described GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. have jointly disclosed new GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.
Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. have jointly patented GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
